Strategy Development for Treating Cutaneous Leishmaniasis
Author Information
Author(s): Modabber Farrokh, Buffet Pierre A, Torreele Els, Milon Geneviève, Croft Simon L
Primary Institution: Drugs for Neglected Diseases Initiative (DNDi)
Hypothesis
What strategies can be developed to improve the treatment of cutaneous leishmaniasis?
Conclusion
There is an urgent need for new treatments for all forms of cutaneous leishmaniasis, and immuno-chemotherapy shows strong potential.
Supporting Evidence
- The financial and social burdens of cutaneous leishmaniasis are high.
- Current treatments are inadequate and require improvement.
- Immuno-chemotherapy has potential to reduce treatment duration and prevent resistance.
- Standardization of clinical trials is necessary for better evaluation of treatments.
Takeaway
Doctors are trying to find better ways to treat a skin disease called cutaneous leishmaniasis, which can leave scars and is often ignored. They want to make sure new treatments are safe and affordable.
Methodology
Experts discussed the socio-economic impact of cutaneous leishmaniasis and proposed strategies for new treatments.
Potential Biases
Limited quantitative data and potential biases in trial designs.
Limitations
The quality of existing clinical trials is poor and requires improvement.
Participant Demographics
Experts from over 14 countries participated in the meeting.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website